ArticleeLife2017
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 73 citations in OpenAlex.
- Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.Cell reports. Medicine · 2021Trial
- Dynamic hinge-motion of PfRIPR revealed by malaria invasion inhibitory antibodies.Nature communications · 2026Article
- Dynamic hinge-motion of PfRIPR revealed by malaria invasion inhibitory antibodies.Nature communications · 2026Article
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria.EMBO molecular medicine · 2026Article
- Erythrocyte invasion in malaria: from molecular mechanisms to rational vaccines.Nature reviews. Microbiology · 2026Review
- PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes.Nature communications · 2026Article
- Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in Senegal.Scientific reports · 2026Article
- Malian field isolates provide insight into Plasmodium malariae intra-erythrocytic development and invasion.PLoS neglected tropical diseases · 2025Article
- Article
- Dynamics of IgM and IgG Antibody Response Profile against Linear B-Cell Epitopes from Exoerythrocytic (CelTOS and TRAP) and Erythrocytic (CyRPA) Phases ofAntibodies (Basel, Switzerland) · 2024Article
- Article
- Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.Nature communications · 2024Article
- Article
- Designing an effective malaria vaccine targeting Plasmodium vivax Duffy-binding protein.Trends in parasitology · 2023Review
- Construction, Expression, and Evaluation of the Naturally Acquired Humoral Immune Response againstInternational journal of molecular sciences · 2023Article
- The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals.Malaria journal · 2023Article
- Toxins from Animal Venoms as a Potential Source of Antimalarials: A Comprehensive Review.Toxins · 2023Review
- Proteome-wide comparison of tertiary protein structures reveals molecular mimicry inFrontiers in parasitology · 2023Article
- A multi-epitope vaccine designed against blood-stage of malaria: an immunoinformatic and structural approach.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Paola FavuzzaMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0002-1394-927X
Elena GuffartRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Marco TamborriniMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Bianca SchererMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Anita M DreyerMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Arne C RuferRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Johannes ErnyRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Joerg HoernschemeyerRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Ralf ThomaRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Georg SchmidRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Bernard GsellRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Araceli LamelasMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Joerg BenzRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Catherine JosephRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Hugues MatileRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Gerd PluschkeMedical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0003-1957-2925
Markus G RudolphRoche Pharmaceutical Research and Early Development, Small Molecule Research, Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Roche (Switzerland) · CHSwiss Tropical and Public Health Institute · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasion of erythrocytes by
Indexed as
Antibodies, ProtozoanAntigens, ProtozoanCrystallography, X-RayMalaria VaccinesModels, MolecularProtein BindingProtein ConformationProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanCyRPA protein, Plasmodium falciparumMalaria VaccinesProtozoan Proteinsbiophysicscrystal structureCyRPAinfectious diseaseinvasion inhibitory antibody<i>p. falciparum</i>Malaria vaccine candidatemicrobiologysialidasestructural biologyβ-propeller
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.